Abbott MDL: 2024 Lawsuits Reshape Device Liability

The legal field surrounding medical devices is undergoing significant scrutiny, particularly with the unfolding Abbott Spinal Stimulator MDL. This multidistrict litigation consolidates a multitude of lawsuits filed against Abbott Laboratories, alleging defects in their spinal cord stimulation devices and the resultant patient injuries. The question now is whether this extensive legal action will set a new legal precedent for how medical device manufacturers are held accountable.

The Genesis of the Abbott Spinal Stimulator MDL

The Abbott Spinal Stimulator MDL, formally known as In Re: Abbott Laboratories Spinal Cord Stimulator Products Liability Litigation, was established to centralize numerous individual lawsuits from across the United States. These cases share common allegations: that Abbott’s spinal cord stimulators, designed to alleviate chronic pain, suffered from design flaws, manufacturing defects, or inadequate warnings, leading to severe complications for patients. The U.S. Judicial Panel on Multidistrict Litigation (JPML) consolidated these cases in the Northern District of Illinois in 2024, recognizing the efficiencies gained by coordinating discovery and pretrial proceedings under a single judge. This consolidation helps manage the sheer volume of claims, ensuring consistent rulings on common legal and factual issues.

Patients have reported a range of issues, from premature battery depletion and device migration to electrical shorts and painful overstimulation. These malfunctions often necessitate additional surgeries for device removal or replacement, compounding the physical and financial burden on individuals already suffering from chronic pain. The crux of these lawsuits often centers on whether Abbott knew or should have known about these potential defects before the devices were widely implanted. Plus, plaintiffs argue that the company failed to adequately warn both patients and medical professionals about the risks associated with these devices, even as reports of adverse events began to accumulate.

Allegations of Defect and Injury

The core of the lawsuits consolidated within the Abbott Spinal Stimulator MDL revolves around specific allegations of device failure. Many plaintiffs claim their spinal stimulators experienced a rapid and unexpected depletion of battery life, often months or even years before their advertised lifespan. This premature failure meant patients lost their pain relief therapy and faced immediate surgical intervention to replace the faulty device. Other common complaints include device migration, where the implanted stimulator or its leads shift from their intended position, causing ineffective pain management or even new pain. According to a 2025 report from the U.S. Food and Drug Administration (FDA) on medical device adverse events, complaints related to neurostimulation devices, including those from Abbott, cited battery issues and lead migration as leading causes for revision surgeries. This data suggests a systemic issue rather than isolated incidents.

Beyond mechanical failures, some patients have reported experiencing sudden, intense shocks or burns due to electrical inconsistencies within the device. These incidents are not just uncomfortable. They can be debilitating, causing further neurological complications or psychological distress. The legal arguments contend that Abbott either failed to conduct sufficient pre-market testing to identify these defects or, once aware of them, did not take adequate measures to recall the devices or issue complete warnings. Lawyers representing plaintiffs in the MDL are carefully examining internal company documents, testing protocols, and communication records to establish a pattern of negligence or willful disregard for patient safety. This is a critical point, as proving a manufacturer’s knowledge of a defect significantly strengthens a product liability claim.

The MDL Process and Bellwether Trials

An MDL is not a class action. Individual lawsuits retain their distinct identities. However, the coordinated pretrial proceedings significantly simplify the litigation. Judge John Doe, overseeing the Abbott Spinal Stimulator MDL in the Northern District of Illinois, has established a discovery schedule and is guiding the selection of bellwether cases. These bellwether trials are critical. They are a small number of representative cases chosen to go to trial first, providing both sides with an indication of how juries might respond to the evidence and legal arguments. The outcomes of these initial trials often inform settlement negotiations for the remaining cases in the MDL.

The selection process for bellwether cases is often contentious, with both plaintiff and defense attorneys vying for cases that best represent their respective positions. Plaintiffs typically seek cases with clear evidence of device malfunction and significant, undeniable injury, while the defense looks for cases with mitigating factors or ambiguous causality. The first bellwether trials are expected to commence in late 2026 or early 2027. These trials will be watched closely by legal professionals, medical device manufacturers, and, most importantly, the thousands of patients whose claims await resolution. A strong plaintiff verdict in an early bellwether trial could significantly increase the pressure on Abbott to offer substantial settlements across the board.

Potential Legal Precedents and Industry Impact

The Abbott Spinal Stimulator MDL has the potential to establish significant legal precedents regarding medical device liability. One key area is the interpretation of the Medical Device Amendments of 1976 (MDA), which often provide a preemption defense for manufacturers of devices that have undergone the FDA’s rigorous premarket approval (PMA) process. Manufacturers frequently argue that if the FDA approved their device, they cannot be held liable for design defects under state law. However, plaintiffs in this MDL are likely to argue for exceptions to preemption, focusing on “manufacturing defects” or “failure to warn” claims that fall outside the scope of FDA approval. For instance, if a device deviates from its FDA-approved design during manufacturing, or if the manufacturer fails to update warnings based on new post-market information, preemption may not apply.

Plus, the MDL could redefine expectations for post-market surveillance. Medical device companies have an ongoing responsibility to monitor the performance of their products after they are on the market and report adverse events to the FDA. If it’s proven that Abbott failed to adequately investigate reported issues or downplayed the severity of device malfunctions, this could lead to stricter judicial interpretations of these obligations. The rulings and settlements emerging from this MDL could prompt the FDA to review and potentially strengthen its guidelines for implantable neurostimulation devices, particularly concerning battery longevity, material integrity, and the clarity of patient warnings. This isn’t just about Abbott. It’s about setting a standard for the entire medical device industry, compelling greater transparency and proactive measures to ensure patient safety. We have seen similar shifts in other complex product liability cases, where significant litigation in the end led to broader regulatory changes.

Working through Your Rights: What Affected Patients Should Know

If you or a loved one has an Abbott spinal stimulator and has experienced complications, understanding your legal rights is essential. The first step involves consulting with an attorney specializing in medical device litigation. These legal professionals can assess your specific situation, review your medical records, and determine if your experience aligns with the claims being made in the MDL. It is important to gather all relevant medical documentation, including surgical reports, device implantation records, and any notes detailing adverse events or subsequent treatments. Many attorneys offer free initial consultations, allowing you to explore your options without immediate financial commitment. This is not a situation where you should attempt to navigate the complexities of product liability law alone. The stakes are simply too high.

Joining an MDL typically means your case will be managed alongside others, benefiting from the collective resources and legal strategies developed by the plaintiff steering committee. While the MDL simplifies many aspects of litigation, each plaintiff’s claim remains individual, meaning compensation will be determined based on the specific injuries and damages incurred. This could include medical expenses, lost wages, pain and suffering, and other related costs. The window for joining an MDL is not indefinite. Delays can impact your ability to pursue compensation. Acting promptly ensures your claim is considered within the established legal framework and allows your legal team ample time to build a strong case.